Alcidion Group (ASX:ALC) Policy Acquisition Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ALC Alcidion Group Ltd ASX:ALC
45 GF Score
Price A$0.11
GF Value A$0.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Alcidion Group Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.

ASX:ALC
45GF Score
Alcidion Group Ltd ASX:ALC
Policy Acquisition Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alcidion Group (ASX:ALC) Overvalued in 2026?

Based on GuruFocus' analysis, Alcidion Group stock appears to be overvalued. The current stock price of A$0.11 is trading 5% above its estimated GF Value™ of A$0.10. GuruFocus considers Alcidion Group to be Fairly Valued.

Key valuation signals for ASX:ALC:

  • Policy Acquisition Expense:
  • GF Value™: A$0.10 vs. price of A$0.11 (5% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the ASX:ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alcidion Group Business Description

Address 9 Yarra Street, Level 10, South Yarra, Melbourne, VIC, AUS, 3141
Alcidion Group Ltd is a provider of intelligent informatics software. It offers a fully integrated digital patient care platform that includes a clinical decision support (CDS) system, Electronic Patient Record (EPR), and Patient Administration System (PAS). Alcidion is engaged in the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of healthcare software products from its strategic partners, and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in the United Kingdom, Australia, and New Zealand. The company generates maximum revenue from the United Kingdom.
45GF Score

Get the complete analysis for ASX:ALC

Policy Acquisition Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.10
GF Value